Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zeltiq's CoolSculpting

This article was originally published in The Gray Sheet

Executive Summary

Non-invasive fat reduction system will be available in the U.S. immediately after receiving 510(k) clearance, announced Sept. 8. Zeltiq received a CE mark in September 2009 for the controlled cooling technology (1"The Gray Sheet" June 7, 2010). The non-surgical substitute for liposuction is based on the natural biologic susceptibility of fat cells to cold. The CoolSculpting system kills underlying fat cells and does not affect the skin tissue, the firm explains

You may also be interested in...

Financings In Brief

Zeltiq Aesthetics raises $25 million: Fat reduction technology developer raises $25 million in a "Series D" private placement led by Aisling Capital, announced June 2. The funds will help Zeltiq Aesthetics "scale up globally," notes CEO Gordie Nye. The firm received European CE Mark approval last September for non-invasive fat layer reduction with its Zeltiq system, which is based on Cryolipolysis controlled cooling technology. The non-surgical alternative to liposuction relies on the natural biologic vulnerability of fat cells to cold. It "is designed to only kill fat cells and not cause the injury to the skin or other tissue that results from liposuction," the company claims. In the U.S., the system is cleared for dermatologic applications; an application is pending for fat-cell reduction, Zeltiq says. Based in Pleasanton, Calif., Zeltiq has raised $50 million since it was founded in 2005

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts